American Society for Transplantation and Cellular Therapy | Strategic Alliance Partners

home / partners / organizations / astct
ASTCT

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals from more than 50 countries. Our mission is dedicated to improving the application and success of hematopoietic cell transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field.

We offer membership options to physicians, investigators, advanced practice professionals, pharmacists, transplant nurses and administrative staff. In addition, we offer free membership to in-training professionals. Learn more about ASTCT.

Subscribe to ASTCT Communications

Create an ASTCT account to receive ASTCT communications.

Latest from American Society for Transplantation and Cellular Therapy

Outcomes of Patients on Transplant Waiting Lists: Q&A with Dr. Giancarlo Fatobene

Outcomes of Patients on Transplant Waiting Lists: Q&A with Dr. Giancarlo Fatobene

Giancarlo Fatobene, MD;Andrés Gómez De León, MD
June 16th 2022

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

KIR-ligand Mismatch in CBT Outcomes Differ Based on GVHD Prophylaxes

KIR-ligand Mismatch in CBT Outcomes Differ Based on GVHD Prophylaxes

American Society for Transplantation and Cellular Therapy
November 22nd 2021

ASTCT recently published an article in their journal Nucleus detailing the use of killer immunoglobulin-like receptor–ligand mismatch and its impact on graft versus host disease.

Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT

Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT

American Society for Transplantation and Cellular Therapy
November 15th 2021

ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.

Learn the Latest In CAR T with ASTCT Webinars

Learn the Latest In CAR T with ASTCT Webinars

American Society for Transplantation and Cellular Therapy
November 8th 2021

Join ASTCT for a series of webinars that focus on topics relating to CAR T.

Interim Findings from the EQUATE Study Demonstrate Safety and Efficacy of Itolizumab

Interim Findings from the EQUATE Study Demonstrate Safety and Efficacy of Itolizumab

American Society for Transplantation and Cellular Therapy
November 8th 2021

ASTCT recently published an article in their journal Nucleus detailing the EQUATE study and its use of itolizumab.

UK Researchers Develop Simplified Manufacturing Process for CAR T Cells

UK Researchers Develop Simplified Manufacturing Process for CAR T Cells

American Society for Transplantation and Cellular Therapy
November 1st 2021

ASTCT recently published an article in their journal Nucleus detailing a simplified manufacturing process for CAR T cells.

Chinese Researchers Identify Risk Factors for Poor Treatment Response to CAR T Therapy in ALL Patients

Chinese Researchers Identify Risk Factors for Poor Treatment Response to CAR T Therapy in ALL Patients

American Society for Transplantation and Cellular Therapy
October 25th 2021

ASTCT recently published an article in their journal Nucleus detailing CAR T therapy in patients with acute lymphoblastic leukemia.

Anti-SARS-CoV-2 mRNA Vaccination After CAR T Therapy “Is Safe but Seroconversion Rate Is Low”

Anti-SARS-CoV-2 mRNA Vaccination After CAR T Therapy “Is Safe but Seroconversion Rate Is Low”

American Society for Transplantation and Cellular Therapy
October 18th 2021

ASTCT recently published an article in their journal Nucleus detailing the COVID-19 vaccine after CAR T therapy.

Rapamycin Pre-Treatment of CAR T Cells “May Enhance Therapeutic Efficacy Against AML”

Rapamycin Pre-Treatment of CAR T Cells “May Enhance Therapeutic Efficacy Against AML”

American Society for Transplantation and Cellular Therapy
October 4th 2021

A recently published article on CAR T cells in patients with acute myeloid leukemia is featured by CancerNetwork's Strategic Alliance Partner ASTCT.

Infusion of HER2-Specific CAR T Cells into Brain or CNS “Feasible” in Pediatric Patients

Infusion of HER2-Specific CAR T Cells into Brain or CNS “Feasible” in Pediatric Patients

American Society for Transplantation and Cellular Therapy
September 27th 2021

ASTCT recently published an article in their journal Nucleus detailing CAR T-cell in pediatric patients with brain cancer.

A Deep Dive On Early Time-to-Tocilizumab

A Deep Dive On Early Time-to-Tocilizumab

American Society for Transplantation and Cellular Therapy
September 20th 2021

The latest episode of the ASTCT Talks features Rahul Banerjee, MD, on bone marrow transplant and CAR-T therapy.

Outpatient Haploidentical Stem Cell Transplantation

Outpatient Haploidentical Stem Cell Transplantation

American Society for Transplantation and Cellular Therapy
September 14th 2021

The latest episode of the ASTCT Talks episode features a discussion from Andrés Gómez De León, MD, and Perla Colunga, MD, on outpatient haploidentical stem cell transplantation.

Advancements in Immunotherapies With John DiPersio, MD, PhD

Advancements in Immunotherapies With John DiPersio, MD, PhD

American Society for Transplantation and Cellular Therapy
September 13th 2021

The latest episode of the ASTCT Talks episode features John DiPersio, MD, PhD, on emerging therapies in the treatment of acute myeloid leukemia.

Illustration of a viral strand of COVID-19

Effective T-Cell Immunity Against Various Coronaviruses Is Possible in Stem Cell Transplant Recipients

Kristie L. Kahl
February 9th 2021

Findings from a poster presentation at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR suggest the feasibility of successful vaccinations against coronaviruses in patients with hematologic malignancies following stem cell transplant.

<123